Search Ontology:
ChEBI
paroxetine maleate
- Term ID
- CHEBI:64194
- Synonyms
-
- (-)-alpha-4-(4-Fluorophenyl)-3-(1,3-benzdioxolyl-(3))-oxymethyl piperidine maleate
- (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (2Z)-but-2-enedioate
- (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine maleate
- (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidinium (2Z)-3-carboxyacrylate
- trans-(-)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine maleate
- Definition
- A maleate salt obtained by reaction of paroxetine with one equivalent of maleic acid. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.
- References
-
- CAS:64006-44-6
- DrugBank:DB00715
- Patent:EP1078925
- Patent:EP269303
- Patent:US4745122
- Patent:US5874447
- Patent:US6440459
- Reaxys:14623212
- Ontology
- ChEBI ( EBI )
- is a type of
-
- has_part
-
- has_role
-
Phenotype
Phenotype resulting from paroxetine maleate
Phenotype where environments contain paroxetine maleate
Phenotype modified by environments containing paroxetine maleate
Human Disease / Model Data